Winnergy Medical PCL

Winnergy Medical PCL maintains a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium risk, with a current ratio of 1.75, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of 18.25 million THB supports operational flexibility, though operating cash flow is negative at -10.55 million THB, signaling potential short-term cash flow constraints. Profitability metrics show a return on equity of 2.39% and a return on assets of 1.34%, both below the typical thresholds for high-performing healthcare firms. These figures suggest that the company is generating modest returns relative to its equity and asset base, which may indicate inefficiencies in capital utilization or pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution across different markets. Looking ahead, the company is projected to experience a modest growth trajectory, with no specific numeric deltas provided in the outlook. Historical revenue growth is not disclosed, but the current financial position suggests a cautious approach to expansion. The company's capital expenditure of -39.46 million THB indicates a net outflow, potentially signaling investment in new facilities or equipment. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could constrain its ability to fund operations or respond to unexpected financial demands. No significant dilution sources are identified, and the company has not issued additional shares recently. Recent events include the latest financial filing, which provides the most recent snapshot of the company's financial health. No recent earnings call transcripts or major regulatory filings are disclosed, limiting insight into management's strategic direction or emerging risks.